Side-by-side comparison

ABBV vs PFE — Side-by-side comparison

PFE screens cheaper on EV/FCF, PFE has the higher ROIC, PFE has grown revenue faster over five years, and ABBV has the cleaner balance sheet by net debt / EBITDA.

ABBV

AbbVie Inc.

Price

$215.70

Market cap

$346.8B

Day %

N/A

PFE

Pfizer Inc.

Price

$25.90

Market cap

$135.4B

Day %

N/A

Peer Comparison

Target stock against 1 market-cap comparable peer.

Heat map: red worst to green best


ABBV Target	AbbVie Inc.	$346.8B	91.4x	22.8x	6.9%	6.0%	29.1%	N/A	3.7x	N/A
PFE	Pfizer Inc.	$135.4B	19.0x	14.8x	9.0%	8.5%	14.5%	N/A	N/A	N/A

ABBV implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

22.8x

FCF yield

5.1%

5Y rev CAGR

6.0%

PFE implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

14.8x

FCF yield

6.7%

5Y rev CAGR

8.5%

5Y indexed stock chart

Static Recharts view indexed to 100 from available annual per-share data.

Quality Scorecard

Build-time composite score for ABBV.

Grade C

/ 100

Quality Scorecard

Build-time composite score for PFE.

Grade D

/ 100